Terumo (4543) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
10 Aug, 2026Executive summary
Achieved record-high quarterly revenue of JPY 311.8 billion, up 19.9% year-over-year, driven by strong global demand, especially in the Americas, and favorable FX rates.
Operating profit rose 60.1% year-over-year to JPY 89.5 billion, supported by a U.S. tariff refund and one-time settlement income.
Adjusted operating profit grew 34.7% to JPY 79.6 billion; profit attributable to owners jumped 68.3% to JPY 70.4 billion.
Full-year profit guidance revised upward to reflect one-time gains, while revenue outlook remains unchanged.
Comprehensive income soared to JPY 99.6 billion, mainly due to FX translation gains.
Financial highlights
Revenue increased 19.9% year-over-year to JPY 311.8 billion, with overseas revenue up 24.1% and Japan up 3.7%.
Operating profit reached JPY 89.5 billion, up 60.1% year-over-year; adjusted operating profit rose 34.7% to JPY 79.6 billion.
Gross margin improved to 57.3% from 56.0% year-over-year.
Free cash flow rose 331% year-over-year to JPY 46.2 billion.
Basic EPS increased to JPY 47.74, up from JPY 28.37.
Outlook and guidance
Full-year revenue outlook maintained at JPY 1.239 trillion (+9.5% YoY).
Adjusted operating profit guidance raised to JPY 274.5 billion (+25.1% YoY); OP margin expected at 20.8%.
Profit attributable to owners forecast at JPY 193.1 billion (+42.1% YoY); EPS guidance at JPY 130.91.
Upward revision reflects U.S. tariff refund and settlement proceeds.
Record highs in both revenue and profit expected for FY 2026.
Latest events from Terumo
- FY26 targets robust growth via innovation in organ tech, Africa, C&V, TMCS, and CDMO.4543
Investor Day 2026 - Record revenue and profit, with double-digit growth expected to continue in FY2026/2027.4543
Q4 2026 - Record revenue and profit growth driven by global demand and strategic acquisitions.4543
Q3 2026 - Innovation, M&A, and new launches fuel global growth and margin expansion.4543
44th Annual J.P. Morgan Healthcare Conference - $1.5B acquisition accelerates entry into organ transplantation, driving growth and innovation.4543
M&A Announcement - Record sales and profit surge drive raised guidance, innovation, and share split.4543
Q2 2025 - Record revenue and profit growth, with double-digit gains and improved margins.4543
Q1 2025 - Record revenue and profit growth, with global expansion and CDMO investment; tariff risks persist.4543
Q4 2025 - Record revenue and profit growth driven by global demand, pricing, and FX gains.4543
Q3 2025